205 related articles for article (PubMed ID: 18422476)
1. Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
Stephan C
Expert Opin Pharmacother; 2008 May; 9(7):1197-209. PubMed ID: 18422476
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.
Gafni RI; Hazra R; Reynolds JC; Maldarelli F; Tullio AN; DeCarlo E; Worrell CJ; Flaherty JF; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2006 Sep; 118(3):e711-8. PubMed ID: 16923923
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy: the final results of study GS-US-104-0321.
Della Negra M; De Carvalho AP; De Aquino MZ; Pinto JA; Da Silva MT; Andreatta KN; Graham B; Liu YP; Quirk EK
Pediatr Infect Dis J; 2015 Apr; 34(4):398-405. PubMed ID: 25599284
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL
Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir disoproxil fumarate.
Gallant JE; Deresinski S
Clin Infect Dis; 2003 Oct; 37(7):944-50. PubMed ID: 13130407
[TBL] [Abstract][Full Text] [Related]
6. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
Valantin MA; Bittar R; de Truchis P; Bollens D; Slama L; Giral P; Bonnefont-Rousselot D; Pétour P; Aubron-Olivier C; Costagliola D; Katlama C;
J Antimicrob Chemother; 2010 Mar; 65(3):556-61. PubMed ID: 20053692
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
Fung HB; Stone EA; Piacenti FJ
Clin Ther; 2002 Oct; 24(10):1515-48. PubMed ID: 12462284
[TBL] [Abstract][Full Text] [Related]
9. [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
Bernardino de la Serna JI; Mora Rillo M; Arribas López JR
Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():7-12. PubMed ID: 19195432
[TBL] [Abstract][Full Text] [Related]
10. A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents.
Della Negra M; de Carvalho AP; de Aquino MZ; da Silva MT; Pinto J; White K; Arterburn S; Liu YP; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
Pediatr Infect Dis J; 2012 May; 31(5):469-73. PubMed ID: 22301477
[TBL] [Abstract][Full Text] [Related]
11. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.
Olin JL; Spooner LM; Klibanov OM
Ann Pharmacother; 2012 Dec; 46(12):1671-7. PubMed ID: 23136357
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir disoproxil fumarate for the treatment of HIV infection.
Pham PA; Gallant JE
Expert Opin Drug Metab Toxicol; 2006 Jun; 2(3):459-69. PubMed ID: 16863446
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naïve patients.
Calza L; Trapani F; Tedeschi S; Piergentili B; Manfredi R; Colangeli V; Viale P
Scand J Infect Dis; 2011 Aug; 43(8):656-60. PubMed ID: 21453205
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of tenofovir treatment.
Rodriguez-Novoa S; Labarga P; Soriano V
Pharmacogenomics; 2009 Oct; 10(10):1675-85. PubMed ID: 19842939
[TBL] [Abstract][Full Text] [Related]
16. Renal safety of tenofovir disoproxil fumarate.
Sax PE; Gallant JE; Klotman PE
AIDS Read; 2007 Feb; 17(2):90-2, 99-104, C3. PubMed ID: 17323508
[TBL] [Abstract][Full Text] [Related]
17. [3 years' data of tenofovir. Confirmed as a valuable building block].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():30-1. PubMed ID: 15373042
[No Abstract] [Full Text] [Related]
18. Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Mikulska M; Taramasso L; Giacobbe DR; Caligiuri P; Bruzzone B; Di Biagio A; Viscoli C
J Med Virol; 2012 Sep; 84(9):1340-3. PubMed ID: 22825811
[TBL] [Abstract][Full Text] [Related]
19. [96-week treatment outcome confirms long term efficacy of tenofovir DF].
Dtsch Med Wochenschr; 2003 May; 128(19):1074-5. PubMed ID: 12774796
[No Abstract] [Full Text] [Related]
20. Long-term follow-up of patients taking tenofovir DF with low-level HIV-1 viremia and the K65R substitution in HIV-1 RT.
Chappell BJ; Margot NA; Miller MD
AIDS; 2007 Mar; 21(6):761-3. PubMed ID: 17413698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
